Jonathan P. Schneck Institute for Cell Engineering, School of Medicine Johns Hopkins University Biography Publications Institution JoVE Articles Jonathan P. Schneck has not added a biography. If you are Jonathan P. Schneck and would like to personalize this page please email our Author Liaison for assistance. Publications Efficient Magnetic Enrichment of Antigen-specific T Cells by Engineering Particle Properties Biomaterials. Dec, 2018 | Pubmed ID: 30312851 Engineering Platforms for T Cell Modulation International Review of Cell and Molecular Biology. 2018 | Pubmed ID: 30262034 ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis Cancer Immunology Research. 02, 2018 | Pubmed ID: 29263161 Tumor and Microenvironment Evolution During Immunotherapy with Nivolumab Cell. Nov, 2017 | Pubmed ID: 29033130 Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation Nano Letters. 11, 2017 | Pubmed ID: 28994285 Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth ACS Nano. 06, 2017 | Pubmed ID: 28589725 Cytotoxic Polyfunctionality Maturation of Cytomegalovirus-pp65-specific CD4 + and CD8 + T-cell Responses in Older Adults Positively Correlates with Response Size Scientific Reports. Jan, 2016 | Pubmed ID: 26778409 Linking Form to Function: Biophysical Aspects of Artificial Antigen Presenting Cell Design Biochimica Et Biophysica Acta. Apr, 2015 | Pubmed ID: 25200637 Magnetic Field-induced T Cell Receptor Clustering by Nanoparticles Enhances T Cell Activation and Stimulates Antitumor Activity ACS Nano. Mar, 2014 | Pubmed ID: 24564881 Sprouty-2 Regulates HIV-specific T Cell Polyfunctionality The Journal of Clinical Investigation. Jan, 2014 | Pubmed ID: 24292711 Particle Shape Dependence of CD8+ T Cell Activation by Artificial Antigen Presenting Cells Biomaterials. Jan, 2014 | Pubmed ID: 24099710 Nanoscale Artificial Antigen Presenting Cells for T Cell Immunotherapy Nanomedicine : Nanotechnology, Biology, and Medicine. Jan, 2014 | Pubmed ID: 23891987 T-cell Memory Responses Elicited by Yellow Fever Vaccine Are Targeted to Overlapping Epitopes Containing Multiple HLA-I and -II Binding Motifs PLoS Neglected Tropical Diseases. 2013 | Pubmed ID: 23383350 Molecular Identification of GD3 As a Suppressor of the Innate Immune Response in Ovarian Cancer Cancer Research. Aug, 2012 | Pubmed ID: 22649190 Quantum Dot Fluorescence Characterizes the Nanoscale Organization of T Cell Receptors for Antigen Biophysical Journal. Dec, 2011 | Pubmed ID: 22261075 Decline of Influenza-specific CD8+ T Cell Repertoire in Healthy Geriatric Donors Immunity & Ageing : I & A. 2011 | Pubmed ID: 21846352 Inhibition of Fas Ligand in NOD Mice Unmasks a Protective Role for IL-10 Against Insulitis Development The American Journal of Pathology. Aug, 2011 | Pubmed ID: 21718680 High-throughput Lectin Microarray-based Analysis of Live Cell Surface Glycosylation Current Protocols in Protein Science / Editorial Board, John E. Coligan ... [et Al.]. Feb, 2011 | Pubmed ID: 21400689 Killer Artificial Antigen-presenting Cells: the Synthetic Embodiment of a 'guided Missile' Immunotherapy. Jul, 2010 | Pubmed ID: 20636007 Dynamic Regulation of Functionally Distinct Virus-specific T Cells Proceedings of the National Academy of Sciences of the United States of America. Feb, 2010 | Pubmed ID: 20133680 Overview of a HLA-Ig Based "Lego-like System" for T Cell Monitoring, Modulation and Expansion Immunologic Research. Jul, 2010 | Pubmed ID: 20087680 In Vivo Administration of Artificial Antigen-presenting Cells Activates Low-avidity T Cells for Treatment of Cancer Cancer Research. Dec, 2009 | Pubmed ID: 19934317 Streptococcus Pneumoniae Serotype 1 Capsular Polysaccharide Induces CD8CD28 Regulatory T Lymphocytes by TCR Crosslinking PLoS Pathogens. Sep, 2009 | Pubmed ID: 19779562 Development of an Artificial-antigen-presenting-cell-based Assay for the Detection of Low-frequency Virus-specific CD8(+) T Cells in Whole Blood, with Application for Measles Virus Clinical and Vaccine Immunology : CVI. Jul, 2009 | Pubmed ID: 19494085 Ex Vivo Induction and Expansion of Natural Killer T Cells by CD1d1-Ig Coated Artificial Antigen Presenting Cells Journal of Immunological Methods. Jul, 2009 | Pubmed ID: 19446558 In Vivo Functional Efficacy of Tumor-specific T Cells Expanded Using HLA-Ig Based Artificial Antigen Presenting Cells (aAPC) Cancer Immunology, Immunotherapy : CII. Feb, 2009 | Pubmed ID: 18563409 Fas-mediated Apoptosis Regulates the Composition of Peripheral Alphabeta T Cell Repertoire by Constitutively Purging out Double Negative T Cells PloS One. 2008 | Pubmed ID: 18941614 Lectin Microarrays Identify Cell-specific and Functionally Significant Cell Surface Glycan Markers Glycobiology. Oct, 2008 | Pubmed ID: 18625848 Killer Artificial Antigen-presenting Cells: a Novel Strategy to Delete Specific T Cells Blood. Apr, 2008 | Pubmed ID: 18096763 Protection from Autoimmune Diabetes and T-cell Lymphoproliferation Induced by FasL Mutation Are Differentially Regulated and Can Be Uncoupled Pharmacologically The American Journal of Pathology. Jul, 2007 | Pubmed ID: 17591957 A Nanoscopic Multivalent Antigen-presenting Carrier for Sensitive Detection and Drug Delivery to T Cells Nanomedicine : Nanotechnology, Biology, and Medicine. Mar, 2007 | Pubmed ID: 17379171 Detection of Antigen-specific T Cells on P/MHC Microarrays Journal of Molecular Recognition : JMR. Jan-Feb, 2007 | Pubmed ID: 17094178 Gld Mutation of Fas Ligand Increases the Frequency and Up-regulates Cell Survival Genes in CD25+CD4+ TR Cells International Immunology. Aug, 2006 | Pubmed ID: 16769751 Evaluation of Topoisomerase-1-specific CD8+ T-cell Response in Systemic Sclerosis Annals of the New York Academy of Sciences. Dec, 2005 | Pubmed ID: 16461796 Antigen/MHC Class II/Ig Dimers for Study of Uveitogenic T Cells: IRBP P161-180 Presented by Both IA and IE Molecules Investigative Ophthalmology & Visual Science. Oct, 2005 | Pubmed ID: 16186361 Artificial Antigen-presenting Cells: Artificial Solutions for Real Diseases Trends in Molecular Medicine. Sep, 2005 | Pubmed ID: 16103011 Technological Advances in Adoptive Immunotherapy Drugs of Today (Barcelona, Spain : 1998). Jan, 2005 | Pubmed ID: 15753966 Effect of Human Papillomavirus-16 Infection on CD8+ T-cell Recognition of a Wild-type Sequence P53264-272 Peptide in Patients with Squamous Cell Carcinoma of the Head and Neck Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2004 | Pubmed ID: 15501971 Quality and Quantity: New Strategies to Improve Immunotherapy of Cancer Trends in Molecular Medicine. May, 2004 | Pubmed ID: 15121045 HLA-Ig-based Artificial Antigen-presenting Cells: Setting the Terms of Engagement Clinical Immunology (Orlando, Fla.). Mar, 2004 | Pubmed ID: 15047202 B220+ Double-negative T Cells Suppress Polyclonal T Cell Activation by a Fas-independent Mechanism That Involves Inhibition of IL-2 Production Journal of Immunology (Baltimore, Md. : 1950). Sep, 2003 | Pubmed ID: 12928389 Ex Vivo Induction and Expansion of Antigen-specific Cytotoxic T Cells by HLA-Ig-coated Artificial Antigen-presenting Cells Nature Medicine. May, 2003 | Pubmed ID: 12704385 Peptide-beta2-microglobulin-MHC Fusion Molecules Bind Antigen-specific T Cells and Can Be Used for Multivalent MHC-Ig Complexes Journal of Immunological Methods. Dec, 2002 | Pubmed ID: 12445736 Probing T Cell Membrane Organization Using Dimeric MHC-Ig Complexes Journal of Immunological Methods. Oct, 2002 | Pubmed ID: 12213346 T Cell Immunodominance and Maintenance of Memory Regulated by Unexpectedly Cross-reactive Pathogens Nature Immunology. Jul, 2002 | Pubmed ID: 12055626 Development and Use of Multimeric Major Histocompatibility Complex Molecules Clinical and Diagnostic Laboratory Immunology. Mar, 2002 | Pubmed ID: 11874855 Lack of Coreceptor Allows Survival of Chronically Stimulated Double-negative Alpha/beta T Cells: Implications for Autoimmunity The Journal of Experimental Medicine. May, 2001 | Pubmed ID: 11369783 Direct Visualization of Antigen-specific T Cells: HTLV-1 Tax11-19- Specific CD8(+) T Cells Are Activated in Peripheral Blood and Accumulate in Cerebrospinal Fluid from HAM/TSP Patients Proceedings of the National Academy of Sciences of the United States of America. Jun, 1998 | Pubmed ID: 9636190 Analysis of the Expression of Peptide-major Histocompatibility Complexes Using High Affinity Soluble Divalent T Cell Receptors The Journal of Experimental Medicine. Oct, 1997 | Pubmed ID: 9334373 Differential Effects of B Cell Receptor and B Cell Receptor-FcgammaRIIB1 Engagement on Docking of Csk to GTPase-activating Protein (GAP)-associated P62 The Journal of Experimental Medicine. Jul, 1997 | Pubmed ID: 9221755 Обогащать и расширять редких антиген специфические Т-клеток с магнитных наночастиц John W. Hickey1,2,3,4, Jonathan P. Schneck2,4 1Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, 2Institute for Cell Engineering, School of Medicine, Johns Hopkins University, 3Institute for Nanobiotechnology, Johns Hopkins University, 4Department of Pathology, School of Medicine, Johns Hopkins University JoVE 58640 Engineering Убийца Искусственный антигенпредставляющих клеток (KaAPC) для эффективного Christian Schütz1, Martin Fleck2,3, Jonathan P. Schneck1, Mathias Oelke1 1Department of Pathology, Institute of Cell Engineering, Johns Hopkins University, 2Department of Internal Medicine I, University of Regensburg, 3Department of Rheumatology, Asklepios Medical Center JoVE 51859 Immunology and Infection HLA-Ig основе искусственного антиген представляющих клеток для эффективного Исключая виво Расширение прав CTL Yen-Ling Chiu1,2, Jonathan P. Schneck3,4, Mathias Oelke3,4 1Immunology Graduate Program, Johns Hopkins University, 2Department of Internal Medicine, Far-Eastern Memorial Hospital, 3Department of Pathology, Johns Hopkins University, 4Institute of Cell Engineering, Johns Hopkins University JoVE 2801 Immunology and Infection
Обогащать и расширять редких антиген специфические Т-клеток с магнитных наночастиц John W. Hickey1,2,3,4, Jonathan P. Schneck2,4 1Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, 2Institute for Cell Engineering, School of Medicine, Johns Hopkins University, 3Institute for Nanobiotechnology, Johns Hopkins University, 4Department of Pathology, School of Medicine, Johns Hopkins University JoVE 58640 Engineering
Убийца Искусственный антигенпредставляющих клеток (KaAPC) для эффективного Christian Schütz1, Martin Fleck2,3, Jonathan P. Schneck1, Mathias Oelke1 1Department of Pathology, Institute of Cell Engineering, Johns Hopkins University, 2Department of Internal Medicine I, University of Regensburg, 3Department of Rheumatology, Asklepios Medical Center JoVE 51859 Immunology and Infection
HLA-Ig основе искусственного антиген представляющих клеток для эффективного Исключая виво Расширение прав CTL Yen-Ling Chiu1,2, Jonathan P. Schneck3,4, Mathias Oelke3,4 1Immunology Graduate Program, Johns Hopkins University, 2Department of Internal Medicine, Far-Eastern Memorial Hospital, 3Department of Pathology, Johns Hopkins University, 4Institute of Cell Engineering, Johns Hopkins University JoVE 2801 Immunology and Infection
